

AMENDMENTS TO THE CLAIMS

Pursuant to 37 C.F.R. 1.121 the following is a complete listing of the claims of the present application and replaces all previous versions.

Listing of the claims:

1. (Canceled)
2. (Currently amended) A method for detecting a polypeptide in a cell or tissue sample, ~~wherein the sample comprises a nerve cell or a nerve progenitor cell and wherein said polypeptide is selected from the group consisting of:~~
 - (a) ~~— a polypeptide encoded by a nucleic acid molecule as represented by the sequence shown in SEQ ID NO: 8 or 9;~~
 - (b) ~~— a polypeptide encoded by a nucleic acid molecule which hybridises to the nucleic acid molecule in (a); or~~
 - (c) ~~— a polypeptide encoded by a nucleic acid molecule which is degenerate to the nucleic acid molecule represented in (a) and (b);~~ said method comprising the steps of:
 - i) ~~— providing a sample comprising a nerve cell or a nerve cell progenitor cell;~~
 - ii) i) contacting ~~said~~ a sample that comprises a nerve cell or a nerve progenitor cell with an agent which binds said the polypeptide that is encoded by a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 8 or 9, wherein said agent comprises an antibody or fragment thereof that binds said polypeptide; and
 - ii) ii) detecting the presence of said polypeptide in said ~~cell~~ sample.
- 3-6. (Canceled)
7. (Currently amended) The method according to ~~Claim 6~~ claim 2, wherein said antibody is a polyclonal antibody or a monoclonal antibody.
8. (Canceled)

9. (Currently amended) The method of claim 2 ~~Claim 6~~, wherein said antibody is provided with means which enable the detection of the antibody bound to said polypeptide.

10. (Currently amended) The method according to Claim 9, wherein said detection means is an enzyme; an isotope label or a fluorescent label.

11-46. (Canceled)

47. (New) The method of claim 2, wherein the antibody or fragment thereof is a fragment that binds said polypeptide, said fragment selected from the group consisting of Fab fragments, F(ab')₂ fragments, F_v fragments, and F_d fragments.

48. (New) The method of claim 2, wherein the antibody or fragment thereof comprises an scFv fragment or domain antibody.

49. (New) The method of claim 2, wherein the antibody or fragment thereof comprises a chimeric antibody or a humanized antibody.

50. (New) A method for detecting an ASPP polypeptide in a nerve cell or a nerve progenitor cell, the method comprising:

(a) contacting a nerve cell or nerve progenitor cell with an agent that binds the ASPP polypeptide that is encoded by a polynucleotide that comprises the nucleotide sequence of SEQ ID NO: 8 or 9, wherein the agent comprises an antibody that binds the polypeptide, or comprises an antigen binding fragment of said antibody; and

(b) detecting polypeptide from the cell bound by the agent.

51. (New) The method of claim 50, wherein the cell is in a tissue sample that comprises a nerve cell or nerve progenitor cell.

52. (New) The method of claim 50, wherein the agent further comprises a detectable label.

53. (New) The method of claim 50, wherein the antibody or fragment thereof binds the polypeptide that is encoded by a polynucleotide that comprises the nucleotide sequence of SEQ ID NO: 8.

54. (New) The method of claim 50, wherein the antibody or fragment thereof binds the polypeptide that is encoded by a polynucleotide that comprises the nucleotide sequence of SEQ ID NO: 9.

55. (New) The method of claim 50, wherein the agent comprises polyclonal antibodies that bind said polypeptide.

56. (New) The method of claim 50, wherein the agent comprises a monoclonal antibody.

57. (New) The method of claim 50, wherein the antibody or fragment thereof is a fragment that binds said polypeptide, said fragment selected from the group consisting of Fab fragments, F(ab')₂ fragments, F_v fragments, and F_d fragments.

58. (New) The method of claim 50, wherein the antibody or fragment thereof comprises an scFv fragment or domain antibody.

59. (New) The method of claim 50, wherein the antibody or fragment thereof comprises a chimeric antibody or a humanized antibody.